Janice Simmons Drug group campaigner to meet PM

Janice Simmons Drug group campaigner to meet PM

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:35 pm #1

Drug group campaigner to meet PM
28 November 2007

<A class=blklnk href="mailto:webdesk@herts24.co.uk">WEB EDITORIAL - webdesk@herts24.co.uk</A>


Prime Minister Gordon Brown is to meet a woman from Huntingdon, who has been campaigning for five years to highlight potential problems with anti-depressants.

Janice Simmons set up the Seroxat User Group in 2002 after discovering that her second husband Jon was addicted to the drug.

Since then thousands of people have contacted her website and the group has provided information to people from all over the world.

Mrs Simmons, 58, a grandmother from Great Stukeley, will travel to Downing Street tomorrow (Thursday), accompanied by Huntingdon MP Jonathan Djanogly and Dr Paul Duckett, from Manchester &shy;University.

She told The Hunts Post: "I never believed we would get this far. Our MP, Jonathan Djanogly, wrote to Tony Blair in July and we received the invite last week."

Mrs Simmons said there is a long list of demands on their shopping list and her group wants:

* To know why - four years since it started - the investigation into GlaxoSmithKline is still ongoing. The MHRA, (the Medicines and Healthcare Regulatory Agency, the body that regulates medicines), is investigating an allegation that GSK withheld information on Seroxat having a higher suicide risk for under 18s. GSK denies this, saying Seroxat was never licensed for children.

* Why a recommendation from a Health Select Committee report in 2005 - which said that the MHRA should become an independent body - has not been implemented.

* The group wants the MHRA to look at independent information about particular drugs - rather than accept information from drug companies.

* Better enforcement of guidelines from NICE (the National Institute for Health and Clinical Excellence) which state that anti-depressants should not be used as a first-line treatment for mild depression.

* The user group says information from its members indicates that many GPs have not heard of the MHRA or the Yellow Card warning system. This is a yellow card doctors and patients are advised to complete to report the side effects of the drugs.

Mrs Simmons set up the group after seeing the addiction of her husband.

Six years before they met, Jon and his first wife were prescribed anti-depressants when their marriage broke down. Jon's wife committed suicide within three weeks of being put on Prozac while 16 years on, Jon is still dependant on anti-depressants.

The Seroxat User Group will also remind Mr Brown that more support groups and funding are needed to help patients trying to withdraw from anti-depressants.

INFORMATION: Contact The Seroxat User Group on www.seroxatusergroup.org.uk e-mail janice@seroxatusergroup.org.uk

<DIV id=linkbox2></DIV>
Last edited by Ch_Isp_Morse on November 29th, 2007, 12:02 am, edited 1 time in total.
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:37 pm #2

<TABLE height="10%" width="92%" align=center>
<TBODY>
<TR>
<TD vAlign=bottom align=middle>
<DIV align=center></DIV>
<DIV align=center>
<P class=style7>




</DIV></TD>
<TD width="51%">
</TD>
<TD vAlign=bottom width="27%">
<P class="style56 style101" align=center><STRONG>

<FONT face=Arial size=1></FONT></STRONG>
</TD></TR>
<TR bgColor=#ffffff>
<TD class=style1 colSpan=3 height=21>
<DIV align=center>
<P class=style96><SPAN class=style135><SPAN class=style26><SPAN class=style21><SPAN class=style139><SPAN class=style112>Home&nbsp;-&nbsp;Who We Are&nbsp;-&nbsp;Information Pack&nbsp;-&nbsp;Campaign News&nbsp;-&nbsp;Discussion Forum&nbsp;-&nbsp;Books</SPAN></SPAN><SPAN class=style112>&nbsp;-&nbsp;Articles </SPAN></SPAN><SPAN class=style21><SPAN class=style112>-</SPAN><SPAN class=style112> Donations </SPAN><SPAN class=style112>-&nbsp;</SPAN><SPAN class=style112>Links</SPAN><SPAN class=style112>&nbsp;</SPAN><SPAN class=style112>-</SPAN><SPAN class=style112>&nbsp;Contact Us</SPAN>
<SPAN class=style112>-&nbsp;</SPAN><SPAN class=style112>Pregnancy & SSRI's</SPAN><SPAN class=style112>&nbsp;-&nbsp;</SPAN><SPAN class=style112>Natural Remedies</SPAN><SPAN class=style112> - Omega 3/Fishoils - Aims of SUG - Aggression - SSRIs - Other News - Videos</SPAN></SPAN></SPAN></SPAN>
</DIV></TD></TR>
<TR bgColor=#0000ff>
<TD class=style1 colSpan=3 height=5>&nbsp;</TD></TR>
<TR>
<TD vAlign=top borderColor=#ffffff width="22%">
<DIV align=center>


<IMG height=111 src="http://www.seroxatusergroup.org.uk/houses%20of%20parliament.jpg" width=167 border=0>
<SPAN class=style134><STRONG><FONT face=Arial>MP Raises Inquiry Into Misuse of Prescription & Over-The-Counter Drugs ...YOUR HELP Is Needed</FONT></STRONG></SPAN>


<STRONG><FONT face=Arial><IMG height=126 src="http://www.seroxatusergroup.org.uk/BBC_Panorama_logo.jpg" width=167></FONT></STRONG>

<SPAN class=style134><STRONG><FONT face=Arial color=#0000ff>Click here to watch the Panorama Special
'Secrets of the Drug Trials'</FONT></STRONG>
</SPAN>


&nbsp;<IMG height=156 src="http://www.seroxatusergroup.org.uk/interview.jpg" width=156>
<SPAN class=style76><SPAN class=style134><STRONG>
<FONT face=Arial>Would You Like To Help With Media Interviews? </FONT>
</STRONG>
<STRONG><FONT face=Arial>We need YOUR HELP</FONT></STRONG>
</SPAN></SPAN>
<SPAN class=style76>


</SPAN><IMG height=218 src="http://www.seroxatusergroup.org.uk/why%20we%20love.gif" width=142 border=0>


</DIV></TD>
<TD class=style21 vAlign=top>
<P align=left><SPAN class=style56><SPAN class=style49><SPAN class=style87>
</SPAN></SPAN></SPAN><STRONG><SPAN class=style126><FONT face=Arial color=#0000ff size=4>&nbsp;&nbsp;&nbsp;Who We Are


</FONT></SPAN>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=Arial><SPAN class=style128>Janice - Co-Ordinator</SPAN>
</FONT></STRONG><SPAN class=style49>
</SPAN><SPAN class=style130>&nbsp;&nbsp;&nbsp;"I am the wife of a long term Seroxat user, and therefore I'm &nbsp;&nbsp;&nbsp;&nbsp;particularly interested in those of you who have partners, family &nbsp;&nbsp;&nbsp;&nbsp;and friends that need help in understanding the problems of &nbsp;&nbsp;&nbsp;&nbsp;taking Seroxat. I know how much it can affect <EM>all members of a &nbsp;&nbsp;&nbsp;&nbsp;family</EM>, as well as the user."

&nbsp;&nbsp;&nbsp;&nbsp;Email:
[url=mailto:janice@seroxatusergroup.org.uk]janice@seroxatusergroup.org.uk [/url]
</SPAN>

<P align=left><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<FONT face=Arial><SPAN class=style128>&nbsp;&nbsp;&nbsp;&nbsp;Andrew - Co-Ordinator</SPAN>
</FONT></STRONG><SPAN class=style49>
</SPAN><SPAN class=style130>&nbsp;&nbsp;&nbsp;"I took Seroxat for approximately four years and despite a &nbsp;&nbsp;&nbsp;&nbsp;protracted withdrawal, I have now successfully withdrawn from &nbsp;&nbsp;&nbsp;&nbsp;the drug. I am 30 years old."</SPAN>

<P class=style117 align=left><SPAN class=style130>&nbsp;&nbsp;&nbsp;&nbsp;Email: <SPAN class=style138><FONT color=#0033ff>andrew@seroxatusergroup.org.uk</SPAN></FONT></SPAN>

<P class=style117><FONT size=4><SPAN class=style126><STRONG><FONT color=#0000ff>&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;</FONT></STRONG></SPAN><SPAN class=style133><SPAN class=style132>Can You Help? </SPAN></SPAN></FONT>

<P class=style117><SPAN class=style131>&nbsp;&nbsp;</SPAN><SPAN class=style130>&nbsp;We are a self funding, non profit making organisation, and hope &nbsp;&nbsp;&nbsp;that you may be able to make a donation towards funding our &nbsp;&nbsp;&nbsp;operational costs.</SPAN>

<P class=style117>&nbsp;&nbsp;&nbsp;<SPAN class=style130>If you are able to, please make a small donation to help us to &nbsp;&nbsp;&nbsp;continue helping you:</SPAN>

<DIV align=center>
<TABLE width="90%" align=center>
<TBODY>
<TR>
<TD vAlign=top width="46%"><SPAN class=style117><IMG height=173 src="http://www.seroxatusergroup.org.uk/twopound.jpg" width=175></SPAN></TD>
<TD vAlign=top width="54%">

<FORM action=https://www.paypal.com/cgi-bin/webscr method=post>
</FORM><SPAN class=style117>
</SPAN></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR></TBODY></TABLE></DIV>
<P class=style117>
</TD>
<TD vAlign=top>
<DIV align=center>
<P align=center>
<IMG height=177 src="http://www.seroxatusergroup.org.uk/notepad.jpg" width=185>
<SPAN class=style134><STRONG><FONT face=Arial>5 Ways You Can
Help Us TODAY!</FONT></STRONG>
</SPAN>


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<IMG height=180 src="http://www.seroxatusergroup.org.uk/depressants.jpg" width=180>
<SPAN class=style70><SPAN class=style112><STRONG><FONT face=Arial>Click here for your
FREE Information Pack</FONT></STRONG>
</SPAN><STRONG><FONT face=Arial color=#0000ff>



</FONT></STRONG></SPAN>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<IMG height=225 src="http://www.seroxatusergroup.org.uk/yellowCard.jpg" width=186>
</DIV>

<DIV align=center>
</DIV></TD></TR>
<TR>
<TD vAlign=top borderColor=#ffffff colSpan=3>
<DIV align=left>
<SPAN class=style101>

<FONT size=1><STRONG>DISCLAIMER: </STRONG>The material on this website is provided for information purposes only and is not a substitute for medical or psychiatric evaluation and treatment. The Seroxat User Group is not engaged in providing professional services or medical advice to the individual reader. Each individual's health is unique. All matters regarding health or a particular health situation should be supervised by a health care professional. The Seroxat User Group shall not be held responsible or liable for any harm or loss allegedly arising, directly or indirectly, from any information on this website. Medical advice should always be sought before discontinuing or changing medication.</FONT></SPAN><SPAN class=style4><SPAN class=style48><SPAN class=style49>
</SPAN></SPAN></SPAN>
</DIV></TD></TR>
<TR>
<TD colSpan=3><FONT size=1>
<HR class=style4 align=center>
</FONT></TD></TR>
<TR vAlign=top>
<TD colSpan=3>
<DIV align=center>
<P class=style134><SPAN class=style135><SPAN class=style96><SPAN class=style26><SPAN class=style21><SPAN class=style140><SPAN class=style112>Home&nbsp;-&nbsp;Who We Are&nbsp;-&nbsp;Information Pack&nbsp;-&nbsp;Campaign News&nbsp;-&nbsp;Discussion Forum&nbsp;-&nbsp;Books</SPAN></SPAN><SPAN class=style112>&nbsp;-&nbsp;Articles </SPAN></SPAN><SPAN class=style21><SPAN class=style112>-</SPAN><SPAN class=style112> Donations </SPAN><SPAN class=style112>-&nbsp;</SPAN><SPAN class=style112>Links</SPAN><SPAN class=style112>&nbsp;</SPAN><SPAN class=style112>-</SPAN><SPAN class=style112>&nbsp;Contact Us</SPAN>
<SPAN class=style112>&nbsp;-&nbsp;</SPAN><SPAN class=style112>Pregnancy & SSRI's</SPAN><SPAN class=style112>&nbsp;-&nbsp;</SPAN><SPAN class=style112>Natural Remedies</SPAN><SPAN class=style112> - Omega 3/Fishoils - Aims of SUG - Aggression - SSRIs - Other News - Videos</SPAN></SPAN></SPAN></SPAN></SPAN>
</DIV></TD></TR>
<TR>
<TD colSpan=3 height=29>
</TD></TR></TBODY></TABLE><!-- Start of StatCounter Code -->
<SCRIPT language=JavaScript>
<!--

function SymError()
{
return true;
}

window.onerror = SymError;

var SymRealWinOpen = window.open;

function SymWinOpen(url, name, attributes)
{
return (new Object());
}

window.open = SymWinOpen;

//-->
</SCRIPT>

<SCRIPT language=javascript type=text/javascript>
var sc_project=722633;
var sc_partition=6;
var sc_security="afc1383e";
var sc_invisible=1;
</SCRIPT>

<SCRIPT language=javascript src="http://www.statcounter.com/counter/counter.js" type=text/javascript></SCRIPT>
<NOSCRIPT></NOSCRIPT><!-- End of StatCounter Code -->
<SCRIPT language=JavaScript>
<!--
var SymRealOnLoad;
var SymRealOnUnload;

function SymOnUnload()
{
window.open = SymWinOpen;
if(SymRealOnUnload != null)
SymRealOnUnload();
}

function SymOnLoad()
{
if(SymRealOnLoad != null)
SymRealOnLoad();
window.open = SymRealWinOpen;
SymRealOnUnload = window.onunload;
window.onunload = SymOnUnload;
}

SymRealOnLoad = window.onload;
window.onload = SymOnLoad;

//-->
</SCRIPT>
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:39 pm #3

<TABLE height="10%" width="90%" align=center>
<TBODY>
<TR>
<TD vAlign=bottom align=middle>
<DIV align=center></DIV>
<DIV align=center>
<P class=style7><IMG id=seroxat_user_group height=115 src="http://web.archive.org/web/20050427235427/http://www.seroxatusergroup.org.uk/seroxat.png" width=154 name=seroxat_user_group>


</DIV></TD>
<TD width="51%">
</TD>
<TD vAlign=bottom width="27%">
<P class="style56 style101"><FONT size=2><SPAN class=style21>Also known as: <SPAN class=style93></SPAN></SPAN>
</FONT><SPAN class=style21><FONT size=2>Paxil </FONT><SPAN class=style93><FONT size=1>(USA)
</FONT><SPAN class=style21><FONT size=2>Aropax</FONT></SPAN><FONT size=1> (Australia, Mexico, South Africa) </FONT></SPAN></SPAN>
<SPAN class=style21><FONT size=2>Deroxat</FONT></SPAN> (France)


</TD></TR>
<TR bgColor=#ffffff>
<TD class=style1 colSpan=3 height=21>
<DIV align=center>
<P class=style96><SPAN class=style26>:: Home ::&nbsp;&nbsp;::&nbsp;Who We Are &nbsp;::&nbsp;&nbsp;::&nbsp;Information Pack &nbsp;::&nbsp;&nbsp;::&nbsp;News ::&nbsp;&nbsp;::&nbsp;Discussion Forum&nbsp;::&nbsp;&nbsp;::&nbsp;Books&nbsp;:: &nbsp;::&nbsp;Links ::&nbsp;&nbsp;&nbsp;::&nbsp;Articles ::&nbsp;&nbsp;:: Contact Us&nbsp;</SPAN><STRONG>::</STRONG>
</DIV></TD></TR>
<TR bgColor=#0000ff>
<TD class=style1 colSpan=3 height=5>&nbsp;</TD></TR>
<TR>
<TD vAlign=top borderColor=#ffffff width="22%">
<DIV align=center>


<IMG height=232 src="http://web.archive.org/web/20050427235427/http://www.seroxatusergroup.org.uk/BeyondProzac.jpg" width=142 border=0>



&nbsp;<IMG height=211 src="http://web.archive.org/web/20050427235427/http://www.seroxatusergroup.org.uk/antiCover.gif" width=142 border=0>
<SPAN class=style76>


</SPAN><IMG height=218 src="http://web.archive.org/web/20050427235427/http://www.seroxatusergroup.org.uk/why%20we%20love.gif" width=142 border=0>




<IMG height=200 src="http://web.archive.org/web/20050427235427/http://www.seroxatusergroup.org.uk/medoc.jpg" width=130 border=0>

</DIV></TD>
<TD class=style21 vAlign=top>
<P align=left><SPAN class=style56><SPAN class=style49><SPAN class=style87>
</SPAN></SPAN></SPAN><STRONG><SPAN class=style126><FONT face=Arial color=#0000ff size=4>&nbsp;&nbsp;&nbsp;Who We Are


</FONT></SPAN>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face=Arial><SPAN class=style128>Janice Simmons - Charity Co-Ordinator</SPAN>
</FONT></STRONG><SPAN class=style49>
</SPAN><SPAN class=style130>&nbsp;&nbsp;&nbsp;"I am the wife of a long term Seroxat user, and therefore I'm &nbsp;&nbsp;&nbsp;&nbsp;particularly interested in those of you who have partners, family &nbsp;&nbsp;&nbsp;&nbsp;and friends that need help in understanding the problems of &nbsp;&nbsp;&nbsp;&nbsp;taking Seroxat. I know how much it can affect <EM>all members of a &nbsp;&nbsp;&nbsp;&nbsp;family</EM>, as well as the user."

&nbsp;&nbsp;&nbsp;&nbsp;Email:
[url=mailto:janice@seroxatusergroup.org.uk]janice@seroxatusergroup.org.uk [/url]
</SPAN>

<P align=left><STRONG>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;


<FONT face=Arial><SPAN class=style128>&nbsp;&nbsp;&nbsp;&nbsp;Andrew Isaac - Charity Co-Ordinator</SPAN>
</FONT></STRONG><SPAN class=style49>
</SPAN><SPAN class=style130>&nbsp;&nbsp;&nbsp;"I took Seroxat for approximately four years and despite a &nbsp;&nbsp;&nbsp;&nbsp;protracted withdrawal, I have now successfully withdrawn from &nbsp;&nbsp;&nbsp;&nbsp;the drug. I am 30 years old and am studying medicine."</SPAN>

<P class=style117 align=left><SPAN class=style130>&nbsp;&nbsp;&nbsp;&nbsp;Email: [url=mailto:andrew@seroxatusergroup.org.uk]andrew@seroxatusergroup.org.uk[/url]</SPAN>

<P class=style117><FONT size=4><SPAN class=style126><STRONG><FONT color=#0000ff>&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;</FONT></STRONG></SPAN><SPAN class=style133><SPAN class=style132>Can You Help? </SPAN></SPAN></FONT>

<P class=style117><SPAN class=style131>&nbsp;&nbsp;</SPAN><SPAN class=style130>&nbsp;We are a self funding, non profit making organisation, and hope &nbsp;&nbsp;&nbsp;that you may be able to make a donation towards funding our &nbsp;&nbsp;&nbsp;operational costs. </SPAN>
</TD>
<TD vAlign=top>
<DIV align=center>
<P align=center>
<IMG height=206 src="http://web.archive.org/web/20050427235427/http://www.seroxatusergroup.org.uk/paxil.jpg" width=203>



&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<IMG height=180 src="http://web.archive.org/web/20050427235427/http://www.seroxatusergroup.org.uk/depressants.jpg" width=180>
<SPAN class=style70><SPAN class=style112><STRONG><FONT face=Arial>Click here for your
FREE Information Pack</FONT></STRONG>
</SPAN><STRONG><FONT face=Arial color=#0000ff>



</FONT></STRONG></SPAN>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<IMG height=225 src="http://web.archive.org/web/20050427235427/http://www.seroxatusergroup.org.uk/yellowCard.jpg" width=186>
</DIV>

</TD></TR>
<TR>
<TD vAlign=top borderColor=#ffffff colSpan=3>
<DIV align=left>
<SPAN class=style101>

<FONT size=1><STRONG>DISCLAIMER: </STRONG>The material on this website is provided for information purposes only and is not a substitute for medical or psychiatric evaluation and treatment. The Seroxat User Group is not engaged in providing professional services or medical advice to the individual reader. Each individual's health is unique. All matters regarding health or a particular health situation should be supervised by a health care professional. The Seroxat User Group shall not be held responsible or liable for any harm or loss allegedly arising, directly or indirectly, from any information on this website. Medical advice should always be sought before discontinuing or changing medication.</FONT></SPAN><SPAN class=style4><SPAN class=style48><SPAN class=style49>
</SPAN></SPAN></SPAN>
</DIV></TD></TR>
<TR>
<TD colSpan=3><FONT size=1>
<HR class=style4 align=center>
</FONT></TD></TR>
<TR vAlign=top>
<TD colSpan=3>
<DIV align=center>
<SPAN class=style114><SPAN class=style26><SPAN class=style49><FONT face=Arial color=#0000ff size=2><STRONG>:: </STRONG></FONT></SPAN><STRONG><FONT face=Arial size=2>Home</FONT></STRONG><STRONG><FONT size=2><FONT face=Arial> <SPAN class=style49><FONT color=#0000ff>::&nbsp;&nbsp;::&nbsp;</FONT></SPAN></FONT></FONT></STRONG><FONT face=Arial color=#0000ff size=2><STRONG>Who We Are</STRONG></FONT><STRONG><FONT size=2><FONT face=Arial> &nbsp;<SPAN class=style49><FONT color=#0000ff>::&nbsp;&nbsp;::&nbsp;</FONT>I<SPAN class=style49>n</SPAN></SPAN></FONT></FONT></STRONG><SPAN class=style49><STRONG><FONT face=Arial size=2>formation Pack</FONT></STRONG></SPAN><STRONG><FONT size=2><FONT face=Arial> <SPAN class=style49><FONT color=#0000ff>::&nbsp;&nbsp;::&nbsp;</FONT></SPAN></FONT></FONT></STRONG><STRONG><FONT face=Arial size=2>News</FONT></STRONG><STRONG><FONT size=2><FONT face=Arial> <SPAN class=style49><FONT color=#0000ff>::&nbsp;&nbsp;::&nbsp;</FONT>Dis</SPAN></FONT></FONT></STRONG><STRONG><FONT face=Arial size=2>cussion Forum</FONT></STRONG><SPAN class=style49><FONT face=Arial color=#0000ff size=2><STRONG>&nbsp;::&nbsp;&nbsp;::&nbsp;</STRONG></FONT><STRONG><FONT face=Arial size=2>Bo</FONT></STRONG></SPAN><STRONG><FONT face=Arial size=2>oks</FONT></STRONG><STRONG><FONT size=2><FONT face=Arial>&nbsp;<SPAN class=style49><FONT color=#0000ff>:: &nbsp;::&nbsp;</FONT>Links<FONT color=#0000ff> ::</FONT></SPAN>&nbsp;&nbsp;&nbsp;<SPAN class=style49><FONT color=#0000ff>::&nbsp;</FONT>Articles</SPAN> <SPAN class=style49><FONT color=#0000ff>::&nbsp;&nbsp;:: </FONT></SPAN></FONT></FONT></STRONG><STRONG><FONT face=Arial size=2>Contact Us</FONT></STRONG><SPAN class=style49><STRONG><FONT face=Arial color=#0000ff size=2>&nbsp;::</FONT></STRONG></SPAN></SPAN></SPAN>

</DIV></TD></TR>
<TR>
<TD colSpan=3 height=29>
</TD></TR></TBODY></TABLE><!-- Start of StatCounter Code -->
<SCRIPT language=JavaScript>
<!--

function SymError()
{
return true;
}

window.onerror = SymError;

var SymRealWinOpen = window.open;

function SymWinOpen(url, name, attributes)
{
return (new Object());
}

window.open = SymWinOpen;

//-->
</SCRIPT>

<SCRIPT language=javascript type=text/javascript>
var sc_project=452607;
var sc_partition=2;
var sc_invisible=1;
</SCRIPT>
<NOSCRIPT></NOSCRIPT><!-- End of StatCounter Code -->
<SCRIPT language=Javascript>
<!--

// FILE ARCHIVED ON 20050427235427 AND RETRIEVED FROM THE
// INTERNET ARCHIVE ON 20071128233816.
// JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.
// ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
// SECTION 108(a)(3)).

var sWayBackCGI = "http://web.archive.org/web/20050427235427/";

function xResolveUrl(url) {
var image = new Image();
image.src = url;
return image.src;
}
function xLateUrl(aCollection, sProp) {
var i = 0;
for(i = 0; i < aCollection.length; i++) {
if (typeof(aCollection[sProp]) == "string") {
if (aCollection[sProp].indexOf("mailto:") == -1 &&
aCollection[sProp].indexOf("javascript:") == -1) {
if(aCollection[sProp].indexOf("http") == 0) {
aCollection[sProp] = sWayBackCGI + aCollection[sProp];
} else {
aCollection[sProp] = sWayBackCGI + xResolveUrl(aCollection[sProp]);
}
}
}
}
}

xLateUrl(document.getElementsByTagName("IMG"),"src");
xLateUrl(document.getElementsByTagName("A"),"href");
xLateUrl(document.getElementsByTagName("AREA"),"href");
xLateUrl(document.getElementsByTagName("OBJECT"),"codebase");
xLateUrl(document.getElementsByTagName("OBJECT"),"data");
xLateUrl(document.getElementsByTagName("APPLET"),"codebase");
xLateUrl(document.getElementsByTagName("APPLET"),"archive");
xLateUrl(document.getElementsByTagName("EMBED"),"src");
xLateUrl(document.getElementsByTagName("BODY"),"background");
var forms = document.getElementsByTagName("FORM");
if (forms) {
var j = 0;
for (j = 0; j < forms.length; j++) {
f = forms[j];
if (typeof(f.action) == "string") {
if(typeof(f.method) == "string") {
if(typeof(f.method) != "post") {
f.action = sWayBackCGI + f.action;
}
}
}
}
}


//-->
</SCRIPT>

<SCRIPT language=JavaScript>
<!--
var SymRealOnLoad;
var SymRealOnUnload;

function SymOnUnload()
{
window.open = SymWinOpen;
if(SymRealOnUnload != null)
SymRealOnUnload();
}

function SymOnLoad()
{
if(SymRealOnLoad != null)
SymRealOnLoad();
window.open = SymRealWinOpen;
SymRealOnUnload = window.onunload;
window.onunload = SymOnUnload;
}

SymRealOnLoad = window.onload;
window.onload = SymOnLoad;

//-->
</SCRIPT>
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:42 pm #4

Sufferers sue 'happy pill' firm for £30million<SPAN class=artByline>By MARTIN DELGADO - <A href="http://www.dailymail.co.uk/pages/dmsear ... ery=martin delgado&in_name=on&in_order_by=relevance+date">More by this author »</A></SPAN> <SPAN class=artDate>Last updated at 00:24am on 18th November 2007</SPAN>
<A class=t11 href="http://www.dailymail.co.uk/pages/live/a ... ents"><IMG height=10 alt=Comments src="http://www.dailymail.co.uk/i/commentIconSm.gif" width=13 border=0> Comments (4)</A>

<DIV id=ArtContentImgBodyR style="WIDTH: 230px"><IMG height=146 alt=Seroxat src="http://img.dailymail.co.uk/i/pix/2007/0 ... 28x146.jpg" width=228 border=1>
'Happy pill': Users say GSK's drug Seroxat is addictive and they want compensation
</DIV>Pharmaceutical giant Glaxo-SmithKline is facing a £30million damages claim from users of its anti-depressant Seroxat.


Lawyers representing patients who insist the bestselling drug is addictive have issued the first of 600 High Court writs against the company, each seeking compensation of up to £50,000.

Since first prescribed in Britain in 1990, Seroxat has been linked to at least 50 suicides of adults and children.

GSK, which makes up to £1billion a year from the drug, is already embroiled in lawsuits with American users, and has been accused of failing to act on warnings that it could have serious side-effects, including mood swings and personality changes.
<STRONG>Expert advice on how to beat depression...</STRONG>

Mark Harvey, of law firm Hugh James, claims Seroxat is "defective" under the 1987 Consumer Protection Act.
He said: "When patients took the drug, not only was there no warning of withdrawal problems, there was also a statement on the data sheet until about 2003 which said you cannot be addicted to Seroxat.

"Unfortunately many people are havingdifficulties as they try to withdraw from the drug, and there are a few who have not been able to stop taking it."
Earlier this year the BBC's Panorama programme alleged that GSK had covered up fears about Seroxat's safety, which the firm strongly denied.

The drug was banned for under-18s in 2003 amid concerns that it contributed to suicide among adolescents with depression, and adult patients have reported that, when they stop taking it, they feel aggressive, reckless and violent towards themselves.

Four years ago a man arrested for armed robbery was cleared after medical experts concluded that his behaviour could have been altered by severe withdrawal symptoms from Seroxat.

GlaxoSmithKline said: "Seroxat has benefited millions of people worldwide.
"We believe the product is not defective and that there is therefore no merit in this litigation."
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:44 pm #5


http://www.seroxatusergroup.org.uk/EMEA ... 202004.pdf

&nbsp;

<P align=justify>Meeting with EMEA on Monday 19th April 2004 at 11.00a.m. until 1.00p.m.
<FONT size=4>
<P align=justify>7 Westferry Circus

<P align=justify>Canary Wharf

<P align=justify>London E14 4HB

<P align=justify>Meeting arranged by Janice Simmons of

<P align=justify>www.seroxatusergroup.org.uk
.

<P align=justify>The European Agency for the Evaluation of Medicinal Products (EMEA) is a decentralised body of the European Union. Its headquarters have been in London since 1995.

<P align=justify>http://www.emea.eu.int/htms/aboutus/emeaoverview.htm

<P align=justify>The EMEA work in conjunction with the CPMP) committee responsible for medicines for human use (CPMP) The meeting was arranged because the EMEA were holding a review into Paroxetine based medicines.
</FONT><FONT face="Comic Sans MS,Comic Sans MS" size=4>
<P align=justify>SUG Members attending the meeting:
</FONT><FONT size=4>
<P align=justify>Janice & John Simmons (SUG

<P align=justify>John Janyga (SUG)

<P align=justify>Derek Scott (OSSG) – http://www.seroxatusergroup.co.uk

<P align=justify>Faye & Peter Elliott (OSSG)

<P align=justify>We were kindly accompanied by:

<P align=justify>Dr Andrew Herxheimer

<P align=justify>Millie Kieve (Chair of APRIL)

<P align=justify>Richard Brook (CEO of MIND)
</FONT><FONT face="Comic Sans MS,Comic Sans MS" size=4>
<P align=justify>Members of EMEA/CPMP were:
</FONT><FONT size=4>
<P align=justify>Dr. Daniel Brasseur Chairman of CPMP

<P align=justify>Dr Panos Tsintis Head of Sector Pharmacovigilance

<P align=justify>Dr. Frances Rotblat UK member based as MHRA London

<P align=justify>Dr Barbara van Zwieten-Boot

<P align=justify>Johan Lindberg

<P align=justify>Anthony Humphries MHRA

<P align=justify>

<P align=justify>We arrived at Canary Wharf at 10.30a.m. Met up with Andrew Herxheimer, John Janyga, and Richard Brook. We all reported to ground floor reception desk where we were greeted by utter chaos because nobody seemed to be able to read or speak English. We were eventually allowed to go up to 4th floor where we met up with Millie. Dr Herxheimer asked Richard Brook what the relationship with the EMEA and Seroxat was and Richard said that Seroxat is EU licensed. So the UK cannot change the licence without Europe.

<P align=justify>We were introduced to all members present from EMEA who quickly said their name we were therefore unable to remember who was who. The environment did not have a very friendly feel to it. I believe most of us felt very uneasy and it seemed that all EMEA members were bored before it began. In fact we were given a very cold welcome.

<P align=justify>We were taken to a large boardroom at approximately 11.10. by Annabella, the Secretary of Dr Panos Tsintis. Each desk had a microphone in front of it and we had to switch these on or off every time we wished to speak. Nobody smiled as we entered the room and it felt more like a court in judgement than a meeting.

<P align=justify>Dr Brasseur declared the meeting open by stating that they wished to be ‘transparent’ and said it was a very unusual procedure to have a meeting with groups such as SUG. He went on to say that as he was led to believe we may have information to give them that may assist them in their review, which they had not seen before. He stated that they would be willing to listen to us and we now had the floor.

<P align=justify>Janice Simmons then introduced everyone present from the SUG/OSSG and their guests.

<P align=justify>

<P align=justify>Derek Scott of OSSG (Online Seroxat Support Group) began by offering Dr Brasseur documents which were from the internal files of GSK asking if they had seen these before. These documents stated that in trials Seroxat showed no benefits to under 18’s. They enquired as to whether the documents were those that were printed in the Canadian Journal. Derek said yes and they said they already knew about this documentation but could Derek summarise it for them.

<P align=justify>Richard Brook said the document shows that 5 years ago GSK knew the results of trials and made a decision not to make it public for commercial reasons.

<P align=justify>Derek asked "What is the EMEA going to do about this?"

<P align=justify>He was told in no uncertain terms that the purpose of the discussion today is to add any information to the EMEA review.

<P align=justify>Janice Simmons asked if they were interested in personal experiences – is this important for your review. Janice offered to obtain questionnaires from all the Seroxat Group if necessary and hand them in to the EMEA. She was told that personal experiences were important to them but there would probably not be enough time to do this. Janice also stated that GP’s were prescribing antidepressants and then had no idea how to wean patients off properly. She said that most GP’s informed their patients to wean off by taking 1 x tablet every other day for 2 weeks and then stop. Janice said this did not work for many, many people and GP’s mistook this for recurring depression instead of withdrawal symptoms.

<P align=justify>

<P align=justify>John Janyga explained that he had made a suicide attempt when initially taking Seroxat and how quickly the feelings occurred. He stated that he had lost 6 years of his life and is very concerned about the thousands of people who are suffering.

<P align=justify>Janice said the group represents over 10,000 people all of whom have suffered adverse effects/withdrawal symptoms of Seroxat. She said her husband John had been on Seroxat since 1991, had made a suicide attempt when initially prescribed the drug and was unable to get off it after 5 attempts. His 1st wife had committed suicide on the 3rd attempt, within 3 weeks of being prescribed Prozac. Janice stated that considering the size of the group present today they had first hand knowledge of 3 suicide attempts - what did that tell them? Janice also stated that she had been offered the drugs 4 times since her mothers death 2 years ago because she was feeling very sad, but she said she refused the drugs as it was part of life and the pain would ease in time.

<P align=justify>John Janyga then enquired about safety concerns and Seroxat. He quoted the ‘Mission Statement’ from the EMEA web site about the high level of protection for the public and in light of the evidence that they had allowed an unsafe drug to be licensed how did they now judge their mission statement?

<P align=justify>The answer to John was that they will not allude to the safety of the drug until after the review which involves many countries.

<P align=justify>Tony Humphries of EMEA told us that in a month’s time there would be 25 countries represented by the EMEA.

<P align=justify>

<P align=justify>We were told that they were only interested in scientific data, several times, but when asked what they were considering in their review they would not or could not tell us.

<P align=justify>Dr Tsintis told us that GSK and other drug companies give their opinions and information regarding their drugs to the EMEA on a regular basis.

<P align=justify>Andrew Herxheimer asked if they could explain how the review is organised and what sources of information they have. If you tell us what you are doing then we can ask you the relevant questions.

<P align=justify>There were no direct answers to Andrew’s question.

<P align=justify>We were then told again that is was a very rare event for them to listen to patient groups by Dr Brasseur.

<P align=justify>Richard Brook enquired as to where they gained their sources of information for their review. Had they seen the FDA reports recently? Are they looking at SSRI’s in general or just Paroxetine? He told them that consumer reporting was very important did they agree, Have you seen reports by Dr Healy. Have they seen BMJ article regarding random clinical trials which are suspect. Pharmacological working of Seroxat. Legislation. Consumer Protection is important.

<P align=justify>Dr Tsintis stated that drug companies have to report any adverse effects to EMEA within weeks/months of drug being released. Richard Brook stated that it took two and a half years before GSK presented information that their drug was dangerous for children how did they get away with that. Look of surprise on his face/ I cannot answer that one. So he didn’t.

<P align=justify>

<P align=justify>Dr Brasseur shrugged his shoulders and said "the obligation is there!" and looked very helpless.

<P align=justify>Faye Elliott spoke about her support group and how she had been affected by the drug. She stated that she had lost 9 years of her life to the drug. She stated that she had successfully withdrawn from the drug over the course of 1 year but only felt 50% of the person she was. She suffered from bad memory and lack of concentration.

<P align=justify>Janice Simmons stated that the MHRA were found to have committee members on their review who had shares in GSK did they know whether their committee members had financial interests. Dr Brasseur said no they did not, as far as he knew. Janice said well Ian Hudson is a committee member and he has shares in GSK and used to work for them. Dr Frances Rotblat, member of EMEA jumped to his defence immediately, stating that he was instructed to leave the room if and when Seroxat was discussed. Janice stated that she did not think it could be a fair and just review with this going on.

<P align=justify>Andrew stated that in the last 4-5 months he had personally been requested to write reports for people who have committed crimes during emotional turmoil while on these drugs. He said that none of these cases ever get into pharmacovigilance reports and he thinks this is the tip of the iceberg.

<P align=justify>Andrew then held up two issues of "The Journal of Risk and Safety in Medicine" and asked if they had ever seen this journal. Did they have a library and were these journals in it? Nobody from EMEA seemed very sure about this.

<P align=justify>

<P align=justify>Anthony Humphries eventually stated that yes, they did have a library but they were not aware of the journals. Dr Brasseur asked Andrew to give them the journals. He refused stating that he would send them copies.

<P align=justify>Janice Simmons said that as the trials for Seroxat were only carried out for 1 year nobody knows what happens to people who have been on the drugs long term. She asked if they were concerned about this. All members of EMEA were unsure whether this was true. One said no it must be longer. Another said it was 3 years. Janice stated that she had heard the facts from Dr Benbow of GSK and it was definitely 1 year. They agreed that if it was a fact from GSK it must be true. There were a lot of notes written by EMEA regarding this item. Janice said she would like to see help for these people as nobody seemed to care.

<P align=justify>Janice asked if they knew why GSK had taken out the statement ‘this drug is not addictive’ from their PIL last year. They could not answer this as they did not seem to know it had been changed. Janice said that Dr Benbow said the reason they had removed the statement was because the public did not understand it.

<P align=justify>Janice stated that organisations such as EMEA, MHRA. GP’s had had it their own way for far too long and now we the general public are on your tails. We want to know what is going on and what has been hidden behind the curtains over the years, we have the right to know as it is our lives that you are messing with. Anthony Humphries of EMEA asked if he could reply on this one. He said he totally agreed with Janice and it was a good thing that the general public could have access to this information as it had been a closed shop for far too long. But some information would still remain secret unfortunately.

<P align=justify>

<P align=justify>He referred to pre 1995 licences which were impenetrable around EU and there was no way of finding out anything about licensing or why drug licences were suspended. Companies could file and withdraw information but now if the committee says a drug is not good the company must explain.

<P align=justify>Richard Brook asked if the EMEA would tell us when the review was to be concluded. They said they could not tell us but there was a legal time frame and it would be concluded very soon.

<P align=justify>Richard Brook asked if they had looked at the FDA hearings and how people in authority had changed their minds after one day of listening to people’s experiences. He also said there is some evidence as to why Seroxat works the way it does although it may not yet have been peer reviewed – it is cutting edge stuff. He also mentioned the class action in the UK to which some of the EMEA members looked very puzzled. Richard Brook also stated that when he was on the MHRA review committee the MHRA reports of the EU work was quite disturbing.

<P align=justify>Richard Brook said that he had met with the German regulator at the FDA meeting and he had informed Richard that he would vote against, whatever the evidence, due to generic commercial interests.

<P align=justify>Andrew Herxheimer stated that reports from patients were totally different from Yellow Card Reports completed by doctors. He said suicidal ideation where a doctor is the judge will probably be linked to depression and not the drug and therefore would not be reported.

<P align=justify>

<P align=justify>John Janyga added that in his own experience the speed at which the suicidal ideation took over was very sudden and happened within a very short space of time. He said it is very important that this should be looked at in detail as it is a very serious subject. Survival instinct is taken from you and he said he could not emphasis this strongly enough how quickly it takes over.

<P align=justify>Richard Brook stated that in the USA GlaxoSmithKline are settling out of court suicide claims for 4-5million dollars a claim and not contesting in court due to the belief that they would lose the cases in court.

<P align=justify>John Janyga said that he could not help but get the feeling that transparency and openness is a little distant and that we had come along today for this meeting in the hopes of everybody being just that. John also stated that the public’s trust in the government regulatory system is not confident at the moment.

<P align=justify>Dr Brasseur said the purpose is to find a better way out and asked ‘You say you are not trusting?’ He then said the point is to take the right decision not just the popular decision. He said ‘we have a legal framework and there are limitations set. We are doing our best.’

<P align=justify>John Janyga said that he could not believe the standard of GP prescribing over the past 5 years. There has been a dramatic increase in prescribing due to other services not being available. He said that mental health services, resources and funding had been appalling for the last 30 years.

<P align=justify>Dr Barbara van Zwieten-Boot stated ‘you should realise who we are as an organisation, we cannot instruct doctors on how to prescribe.’

<P align=justify>

<P align=justify>Dr Frances Rotblat said ‘we are frustrated about what we can/cannot do. The UK are behind and are limited by law in what they can do’.

<P align=justify>Millie Kieve stated ‘You can’t regulate what the doctor prescribes but you can regulate what influences the doctor to prescribe. She then went on to say ‘is the working party on PIL’s aware that if working with patient groups that are funded by pharmaceutical companies or even set up by them, they may not get a true picture of the drugs adverse effects?’

<P align=justify>Dr Brasseur concluded the meeting by saying he is aware that the system is far from perfect and the more countries that are involved in the EU the more challenging it becomes.

<P align=justify>Janice Simmons then thanked the Chairman, Dr Brasseur for allowing us to attend the meeting with them and we all left the room.
</FONT>
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:49 pm #6

Drug group campaigner to meet PM
28 November 2007

<A class=blklnk href="mailto:webdesk@herts24.co.uk">WEB EDITORIAL - webdesk@herts24.co.uk</A>


Prime Minister Gordon Brown is to meet a woman from Huntingdon, who has been campaigning for five years to highlight potential problems with anti-depressants.

Janice Simmons set up the Seroxat User Group in 2002 after discovering that her second husband Jon was addicted to the drug.

Since then thousands of people have contacted her website and the group has provided information to people from all over the world.

Mrs Simmons, 58, a grandmother from Great Stukeley, will travel to Downing Street tomorrow (Thursday), accompanied by Huntingdon MP Jonathan Djanogly and Dr Paul Duckett, from Manchester &shy;University.

She told The Hunts Post: "I never believed we would get this far. Our MP, Jonathan Djanogly, wrote to Tony Blair in July and we received the invite last week."

Mrs Simmons said there is a long list of demands on their shopping list and her group wants:

* To know why - four years since it started - the investigation into GlaxoSmithKline is still ongoing. The MHRA, (the Medicines and Healthcare Regulatory Agency, the body that regulates medicines), is investigating an allegation that GSK withheld information on Seroxat having a higher suicide risk for under 18s. GSK denies this, saying Seroxat was never licensed for children.

* Why a recommendation from a Health Select Committee report in 2005 - which said that the MHRA should become an independent body - has not been implemented.

* The group wants the MHRA to look at independent information about particular drugs - rather than accept information from drug companies.

* Better enforcement of guidelines from NICE (the National Institute for Health and Clinical Excellence) which state that anti-depressants should not be used as a first-line treatment for mild depression.

* The user group says information from its members indicates that many GPs have not heard of the MHRA or the Yellow Card warning system. This is a yellow card doctors and patients are advised to complete to report the side effects of the drugs.

Mrs Simmons set up the group after seeing the addiction of her husband.

Six years before they met, Jon and his first wife were prescribed anti-depressants when their marriage broke down. Jon's wife committed suicide within three weeks of being put on Prozac while 16 years on, Jon is still dependant on anti-depressants.

The Seroxat User Group will also remind Mr Brown that more support groups and funding are needed to help patients trying to withdraw from anti-depressants.

INFORMATION: Contact The Seroxat User Group on www.seroxatusergroup.org.uk e-mail janice@seroxatusergroup.org.uk

<DIV id=linkbox2></DIV>
<STRONG>Mrs. Iris Robinson: <!--Mrs. Iris Robinson--></STRONG>To ask the Secretary of State for Northern Ireland what measures are used in Northern Ireland hospitals to establish consent from a patient for electroconvulsive therapy. [17559]
<A name=st_242></A><!--meta name="Colno" CONTENT="742"--><A name=51017w26.html_spnew2></A>Mr. Woodward: <!--Mr. Woodward-->A standard consent form is used to obtain consent from patients. When a patient is unable to give consent, a second opinion is necessary from an independent doctor appointed by the Mental Health Commission before the procedure can proceed.
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:50 pm #7

<H3 align=center>Electroconvulsive Therapy</H3>
<A name=qn_239></A><!--meta name="Colno" CONTENT="741"--><A name=51017w26.html_wqn1></A>Mrs. Iris Robinson: <!--Mrs. Iris Robinson-->To ask the Secretary of State for Northern Ireland how many individuals have been treated with electroconvulsive therapy in the Province in each of the last 10 years. [17132]
<A name=column_742></A>
&nbsp;
17 Oct 2005 : Column 742W
&nbsp;

<A name=st_241></A><!--meta name="Colno" CONTENT="742"--><A name=51017w26.html_spnew1></A>Mr. Woodward: <!--Mr. Woodward-->The total number of patients who received electroconvulsive therapy (ECT) in each financial year 1994–95 to 2004–05 is provided in the following table.
<TABLE border=1><A name=table_35></A>
Total number of patients who have received electroconvulsive therapy


<TBODY>
<TR vAlign=top>
<TH class=tabletext></TH>
<TH class=tabletext>Number of patients who received ECT </TH></TR>
<TR vAlign=top>
<TD class=tabletext>1994–95</TD>
<TD class=tabletext>1,039 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1995–96</TD>
<TD class=tabletext>1,081 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1996–97</TD>
<TD class=tabletext>936 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1997–98</TD>
<TD class=tabletext>876 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1998–99</TD>
<TD class=tabletext>808 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1999–2000</TD>
<TD class=tabletext>717 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2000–01</TD>
<TD class=tabletext>629 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2001–02</TD>
<TD class=tabletext>659 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2002–03</TD>
<TD class=tabletext>662 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2003–04</TD>
<TD class=tabletext>624 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2004–05</TD>
<TD class=tabletext>472 </TD></TR></TBODY></TABLE>



Note:
Data are collected on a quarterly basis and include both new patients and patients who received ECT previously. Therefore patients may be included in the table more than once over the year if they received ECT in a previous quarter.

Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:52 pm #8

<H3 align=center><B style="COLOR: black; BACKGROUND-COLOR: #ffff66">Electroconvulsive</B> Therapy</H3>
<A name=qn_241></A><!--meta name="Colno" CONTENT="90"--><A name=51024w24.html_wqn7></A>Mrs. Iris Robinson: <!--Mrs. Iris Robinson-->To ask the Secretary of State for Northern Ireland what obligations there are on hospital staff in Northern Ireland who are involved in <B style="COLOR: black; BACKGROUND-COLOR: #ffff66">electroconvulsive</B> therapy procedures to understand the <B style="COLOR: black; BACKGROUND-COLOR: #a0ffff">calibration</B> settings of ECT machines. [17560]

<A name=st_241></A><!--meta name="Colno" CONTENT="90"--><A name=51024w24.html_spnew7></A>Mr. <B style="COLOR: black; BACKGROUND-COLOR: #99ff99">Woodward: </B><!--Mr. Woodward-->Clinical staff, using an ECT machine to provide electro-convulsive therapy, are trained by an appropriately experienced consultant psychiatrist and subsequently use ECT machines only when deemed competent to do so by the consultant psychiatrist.
<A name=subhd_175></A><A name=51024w24.html_sbhd8></A>
<H3 align=center>Freedom of Information</H3>
Last edited by Ch_Isp_Morse on November 29th, 2007, 12:02 am, edited 1 time in total.
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:57 pm #9

<H3 align=center>Electroconvulsive Therapy</H3>
<A name=qn_239></A><!--meta name="Colno" CONTENT="741"--><A name=51017w26.html_wqn1></A>Mrs. Iris Robinson: <!--Mrs. Iris Robinson-->To ask the Secretary of State for Northern Ireland how many individuals have been treated with electroconvulsive therapy in the Province in each of the last 10 years. [17132]
<A name=column_742></A>
&nbsp;
17 Oct 2005 : Column 742W
&nbsp;

<A name=st_241></A><!--meta name="Colno" CONTENT="742"--><A name=51017w26.html_spnew1></A>Mr. Woodward: <!--Mr. Woodward-->The total number of patients who received electroconvulsive therapy (ECT) in each financial year 1994–95 to 2004–05 is provided in the following table.
<TABLE border=1><A name=table_35></A>
Total number of patients who have received electroconvulsive therapy


<TBODY>
<TR vAlign=top>
<TH class=tabletext></TH>
<TH class=tabletext>Number of patients who received ECT </TH></TR>
<TR vAlign=top>
<TD class=tabletext>1994–95</TD>
<TD class=tabletext>1,039 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1995–96</TD>
<TD class=tabletext>1,081 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1996–97</TD>
<TD class=tabletext>936 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1997–98</TD>
<TD class=tabletext>876 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1998–99</TD>
<TD class=tabletext>808 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>1999–2000</TD>
<TD class=tabletext>717 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2000–01</TD>
<TD class=tabletext>629 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2001–02</TD>
<TD class=tabletext>659 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2002–03</TD>
<TD class=tabletext>662 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2003–04</TD>
<TD class=tabletext>624 </TD></TR>
<TR vAlign=top>
<TD class=tabletext>2004–05</TD>
<TD class=tabletext>472 </TD></TR></TBODY></TABLE>



Note:
Data are collected on a quarterly basis and include both new patients and patients who received ECT previously. Therefore patients may be included in the table more than once over the year if they received ECT in a previous quarter.
<H3 align=center>ECT Treatment</H3>
<A name=qn_334></A><!--meta name="Colno" CONTENT="1503"--><A name=50628w32.html_wqn5></A>Mr. Burstow: <!--Mr. Burstow-->To ask the Secretary of State for Health how many people in England have undergone electroconvulsive therapy in each of the past five years; and how many were (a) 50 years or over and (b) 65 years or over. [6395]

<A name=st_334></A><!--meta name="Colno" CONTENT="1503"--><A name=50628w32.html_spnew5></A>Ms Rosie Winterton: <!--Ms Rosie Winterton-->The information is not available in the requested format. The latest information available on electro-convulsive therapy (ECT) is that contained in the Department's publication Statistical Bulletin Electro Convulsive Therapy: Survey covering the period from January 2002 to March 2002, England". This was a follow-up to an earlier survey of the period January to March 1999. Both surveys were undertaken to provide data on ECT that are not currently available elsewhere.

<A name=50628w32.html_para0></A><!--meta name="Speaker" CONTENT="Ms Rosie Winterton"--><A name=stpa_185></A>The 2002 survey confirmed the continuing downward trend in the number of administrations of ECT. It collected information from national health service and independent sector care settings, including nursing homes, on the total number of administrations of ECT in NHS and independent sector care settings including data on sex, age, ethnicity, legal status and method of consent.

<A name=50628w32.html_para1></A><!--meta name="Speaker" CONTENT="Ms Rosie Winterton"--><A name=stpa_186></A>It found that in the period January to March 2002:
  • <P class=tabletext><A name=brev_52></A>2,300 patients received ECT treatment compared to 2,800 in 1999; there were 700 male patients receiving treatment, compared with 1,600 female patients; there were 12,800 administrations of ECT compared to 16,500 in January to March 1999; of the 2,272 patients in England who underwent ECT in 2002, 1,709 were aged 45 and over, and 1,053 were aged 65 and over. This compares to figures of 2,079 and 1,176, respectively, of the total of 2,835 in the 1999 survey.

<A name=50628w32.html_para2></A><!--meta name="Speaker" CONTENT="Ms Rosie Winterton"--><A name=stpa_187></A>Copies of the 2002 survey and the earlier 1999 survey are available in the Library.
<!-- google_ad_section_end -->
&nbsp;
<TABLE width="100%" border=0>
<TBODY>
<TR>
<TD vAlign=top noWrap align=left><FONT face="Arial, Times New Roman, Verdana, Helvetica" size=1>&nbsp;</FONT></TD></TR></TBODY></TABLE>
Quote
Like
Share

Joined: April 1st, 2004, 4:56 pm

November 28th, 2007, 11:59 pm #10

<STRONG>Mrs. Iris Robinson: <!--Mrs. Iris Robinson--></STRONG>To ask the Secretary of State for Northern Ireland what measures are used in Northern Ireland hospitals to establish consent from a patient for electroconvulsive therapy. [17559]
<A name=st_242></A><!--meta name="Colno" CONTENT="742"--><A name=51017w26.html_spnew2></A>Mr. Woodward: <!--Mr. Woodward-->A standard consent form is used to obtain consent from patients. When a patient is unable to give consent, a second opinion is necessary from an independent doctor appointed by the Mental Health Commission before the procedure can proceed.
<A title="" name=rcp>The Royal College of Psychiatrists</A> PATIENT FACTSHEET


ECT (ELECTROCONVULSIVE THERAPY)


Introduction
This leaflet will try to answer some of the questions you may have about ECT. You may wish to know what is ECT? Why is it used? What is it like to have ECT and what the risks and benefits may be?


When you are depressed, it is often quite difficult to concentrate. Don't be concerned if you can't read through all of the leaflet. Just pick out the sections that seem important at the time, and come back to it later. You may wish to use it to help you ask questions of staff, relatives or other patients.

Why is ECT used?
Most people who have ECT are suffering from depression. Although we have tablets for depression some people do not recover completely and others take a long time. ECT is often used for these patients. In severe cases of depression ECT may be the best treatment and it can be life saving.


Why has ECT been recommended for me?
ECT is given for many reasons. Some of the commoner ones are listed below. If you are not sure why you are being given ECT, don't be afraid to ask. It's sometimes difficult to remember things when you are depressed, so you may need to ask several times.


ECT is most commonly used to treat severe depression It may be helpful if you can't take anti-depressant drugs because of the side effects

It may help if you have responded well to ECT in the past

It may be helpful if you feel so overwhelmed by your depression that it's difficult to function at all.

What will actually happen when I have ECT?
For the treatment, you should wear loose clothes, or nightclothes. You will be asked to remove any jewellery, hairslides or false teeth if you have them.


The treatment takes place in a separate room and only takes a few minutes. Other patients will not be able to see you having it. The anaesthetist will ask you to hold out your hand so you can be given an anaesthetic injection. It will make you go to sleep and cause your muscles to relax completely.

You will be given some oxygen to breath as you go off to sleep. Once you are fast asleep, a small electric current is passed across your head and this causes a mild fit in the brain. There is little movement of your body because of the relaxant injection that the anaesthetist gives. When you wake up, you will be back in the waiting area. Once you are wide awake, you will be offered a cup of tea.

What will happen immediately before the treatment?
An ECT treatment involves having an anaesthetic. You will need to fast (have nothing to eat and drink) from about midnight the night before each treatment. This will involve having no breakfast on the morning that you have ECT.


How will I feel immediately after ECT?
Some people wake up with no side effects at all and simply feel very relaxed. Others may feel somewhat confused or have a headache. There will be a nurse with you when you wake up after the treatment to offer you reassurance and make you feel as comfortable as possible.


How does ECT work?
During ECT a small amount of electric current is sent to the brain. This current produces a seizure which affects the entire brain, including the centres which control thinking, mood, appetite and sleep. Repeated treatments alter chemical messages in the brain and bring them back to normal. This helps you begin to recover from your illness.


How well does ECT work?
Over 8 out of 10 depressed patients who receive ECT respond well making ECT the most effective treatment for severe depression. People who have responded to ECT report it makes them feel "like themselves again" and "as if life was worth living again". Severely depressed patients will become more optimistic and less suicidal. Most patients recover their ability to work and lead a productive life after their depression has been treated with a course of ECT.


What is a course of ECT?
ECT is usually given two or three times a week. It is not possible to say exactly how many treatments you may need. Some people get better with as few as two or three treatment sessions, others may need as many as twelve and very occasionally more.


What ECT cannot do?
The effects of ECT will relieve the symptoms of your depression but will not help all your problems. An episode of depression may produce problems with relationships, or problems at home or at work. These problems may still be present after your treatment and you may need further help with these. Hopefully, because the symptoms of your depression are better, you will be able to deal with these other problems more effectively.


What are the side effects of ECT?
Some patients may be confused just after they awaken from the treatment and this generally clears up within an hour or so. Your memory of recent events may be upset and dates, names of friends, public events, addressees and telephone numbers may be temporarily forgotten. In most cases this memory loss goes away within a few days or weeks, although sometimes patients continue to experience memory problems for several months. ECT does not have any long term effects on your memory or your intelligence.


Are there any serious risks from the treatment?
ECT is amongst the safest medical treatments given under general anaesthesia, the risk of death or serious injury with ECT is rare and occurs in about one in 50,000 treatments. For example, this is much lower than that reported for childbirth. Very rarely deaths do occur and these are usually because of heart problems. If you do have heart disease, it may still be possible for you to have ECT safely with special precautions such as heart monitoring. Your doctor will ask another specialist to advise if there are grounds for concern.


What other treatments could I have?
Anti-depressant drugs may be available to treat your particular condition and it is possible that some of them may work as well as ECT. The advantage and disadvantages of other treatments should be discussed with you by your doctor.


Will I have to give my consent? Can I refuse to have ECT?
At some stage before the treatment, you will be asked by your doctor to sign a consent form for ECT. If you sign the form, you are agreeing to have up to a certain number of treatments (usually 6). Before you sign the form, the doctor should explain what the treatment involves, and why you are having it, and should be available to answer any questions you may have about the treatment.


You can refuse to have ECT and you may withdraw your consent at any time, even before the first treatment has been given. The consent form is not a legal document and does not commit you to have the treatment. It is a record that an explanation has been given to you and that you understand to your satisfaction what is going to happen to you. Withdrawal of your consent to ECT will not in any way alter your right to continued treatment with the best alternative methods available.

Very occasionally there are patients who are seriously ill - suicidal, convinced that they are too wicked to be treated, eating and drinking too little to stay alive for much longer.

ECT may be given to patients without their consent under a Section (3) of the Mental Health Act. Even so, an independent psychiatrist, sent by the Mental Health Act Commission, must agree that the treatment is necessary.

Are there any risks in not having ECT as recommended?
If you choose not to accept your doctor's recommendation to have ECT, you may experience a longer and more severe period of illness and disability than might otherwise have been the case. The alternative is drug therapy which also has risks and complications and drug treatment is not necessarily safer than ECT.


The Royal College of Psychiatrists April, 1993 (The above handout may be copied so long as it is copied in full, and is attributed to the Royal College of Psychiatrists, London.)

&nbsp;

<A title=http://www.priory.co.uk/psych/ectolpil.htm#rcp href="http://www.priory.co.uk/psych/ectolpil. ... htm#rcp</A>

&nbsp;
Quote
Like
Share